Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Control of Tumor-Associated Macrophage Alternative Activation by Macrophage Migration Inhibitory Factor

Open access
Yaddanapudi, Kavitha, Putty, Kalyani, Rendon, Beatriz E, Lamont, Gwyneth J, Faughn, Jonathan D, Satoskar, Abhay, Lasnik, Amanda, Eaton, John W, Mitchell, Robert A·2013·The Journal of Immunology

Abstract

Tumor stromal alternatively activated macrophages are important determinants of antitumor T lymphocyte responses, intratumoral neovascularization, and metastatic dissemination. Our recent efforts to investigate the mechanism of macrophage migration inhibitory factor (MIF) in antagonizing antimelanoma immune responses reveal that macrophage-derived MIF participates in macrophage alternative activation in melanoma-bearing mice. Both peripheral and tumor-associated macrophages (TAMs) isolated from melanoma bearing MIF-deficient mice display elevated proinflammatory cytokine expression and reduced anti-inflammatory, immunosuppressive, and proangiogenic gene products compared with macrophages from tumor-bearing MIF wild-type mice. Moreover, TAMs and myeloid-derived suppressor cells from MIF-deficient mice exhibit reduced T lymphocyte immunosuppressive activities compared with those from their wild-type littermates. Corresponding with reduced tumor immunosuppression and neo-angiogenic potential by TAMs, MIF deficiency confers protection against transplantable s.c. melanoma outgrowth and melanoma lung metastatic colonization. Finally, we report for the first time, to our knowledge, that our previously discovered MIF small molecule antagonist, 4-iodo-6-phenylpyrimidine, recapitulates MIF deficiency in vitro and in vivo, and attenuates tumor-polarized macrophage alternative activation, immunosuppression, neoangiogenesis, and melanoma tumor outgrowth. These studies describe an important functional contribution by MIF to TAM alternative activation and provide justification for immunotherapeutic targeting of MIF in melanoma patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1201650

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 180

Metadata

Authors
Yaddanapudi, K., Putty, K., Rendon, B. E., Lamont, G. J., Faughn, J. D., Satoskar, A., Lasnik, A., Eaton, J. W., & Mitchell, R. A.
Venue
The Journal of Immunology
Published
2013-03
Volume
190
Issue
6
Pages
2984-2993
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2142394051
Cited by
180
References
6
FWCI
5.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Control of Tumor-Associated Macrophage Alternative Activation by Macrophage Migration Inhibitory Factor. https://app.cochat.ai/papers/10.4049/jimmunol.1201650
The paper
Yaddanapudi, K., Putty, K., Rendon, B. E., Lamont, G. J., Faughn, J. D., Satoskar, A., Lasnik, A., Eaton, J. W., & Mitchell, R. A. (2013). Control of Tumor-Associated Macrophage Alternative Activation by Macrophage Migration Inhibitory Factor. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1201650

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.